JPRN-UMIN000001752已完成2 期
A phase II study of amrubicin for previously treated small cell lung cancer - Amrubicin for previously treated small cell lung cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pulmonary fibrosis detectable on chest X-ray films 2)Massive pleural effusion, ascites and pericardial effusion required drainage 3)Concomitant malignancy 4)Serious medical complications: uncontrolled angina pectoris, myocardial infarction within 3 months, heart failure. Uncontrolled diabetes mellitus, hypertension, infection (ileus, bleeding, superior vena cava syndrome 5)Symptomatic brain metastasis 6)Pregnant or milk-feeding female. Intention to be pregnant in the future 7)With severe allergy 8)Other clinical difficulties to this study
研究者
相似试验
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35
已完成
不适用
Phase 2 study of amrubicin in previously treated patients with malignant pleural mesotheliomaMalignant pleural mesotheliomaJPRN-UMIN000006381agasaki University Hospital32
已完成
2 期
Phase 2 Study of Amrubicin for patients with recurrent advanced squamous cell lung cancer after first line treatment.Recurrent squamous cell lung cancerJPRN-UMIN000006270Kansai Medical University Hirakata Hospital40
已完成
2 期
Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.small cell lung cancerJPRN-UMIN000011055Kitasato University School of Medicine Department of Respiratory Medicine34
进行中（未招募）
不适用
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC ES - NDPatient with small cell lung cancer.MedDRA version: 6.1Level: PTClassification code 10041068EUCTR2006-001956-11-ITCABRELLIS PHARMACEUTICALS CORPORATIO85